Advertisement Heart disease costs UK economy GBP29 billion a year - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Heart disease costs UK economy GBP29 billion a year

New research from Oxford University has revealed that cardiovascular disease costs the UK economy GBP29 billion a year in healthcare expenditure and lost productivity.

The UK spends more of its healthcare budget on cardiovascular disease than any other country in the European Union, the figures, published in the journal Heart, show.

The research team, from the Health Economics Research Centre at the University of Oxford, base their calculations on all UK residents with diagnosed cardiovascular disease in 2004 and associated costs. These included community health and social services, emergency care, hospital stays, informal care, and the impact on productivity from illness and premature death.

When all these factors were added up, the total costs to the UK economy of cardiovascular disease in 2004 came to GBP29 billion.

The largest component was healthcare, which accounted for 60% of the total. Lost productivity accounted for 23% and informal care cost 17%.

Cardiovascular disease cost the National Health Service (NHS) almost GBP16 billion in 2004, representing 21% of all healthcare expenditure. Private healthcare costs add almost GBP1.5 billion to the tally, representing 18% of overall UK healthcare costs.

These figures represent the highest proportion of healthcare expenditure on cardiovascular disease of any country in the European Union.

Hospital inpatient care was the most expensive component at almost GBP10 billion or nearly two thirds of the NHS bill for cardiovascular disease. Drug costs amounted to almost GBP3 billion.

More than 69 million work days were lost to the disease in 2004, at a cost to the UK economy of almost GBP3 billion.

The researchers suggest that despite the falling rates of illness and death from cardiovascular disease, cost savings are likely to be cancelled out by the rising costs of treatment, the ageing of the population, and the threat to heart health posed by obesity and diabetes.